In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases

被引：0

作者：

Arianna Sala

Silvia Paola Caminiti

Luca Presotto

Andrea Pilotto

Claudio Liguori

Agostino Chiaravalloti

Valentina Garibotto

Giovanni Battista Frisoni

Marcello D’Amelio

Barbara Paghera

Orazio Schillaci

Nicola Mercuri

Alessandro Padovani

Daniela Perani

机构：

[1] Vita-Salute San Raffaele University,In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience

[2] San Raffaele Scientific Institute,Nuclear Medicine Unit

[3] San Raffaele Hospital,Neurology Unit, Department of Clinical and Experimental Sciences

[4] University of Brescia,Division of Neurology, Department of Systems Medicine

[5] Parkinson’s Disease Rehabilitation Centre,Department of Biomedicine and Prevention

[6] FERB ONLUS – S. Isidoro Hospital,Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department

[7] University of Rome “Tor Vergata”,Memory Clinic and LANVIE

[8] University of Rome “Tor Vergata”,Laboratory of Neuroimaging of Aging

[9] IRCCS Neuromed,Department of Experimental Neurosciences

[10] University Hospitals of Geneva,Unit of Molecular Neurosciences, Department of Medicine

[11] and NIMTLab,Nuclear Medicine Unit

[12] Faculty of Medicine,undefined

[13] Geneva University,undefined

[14] University Hospitals and University of Geneva,undefined

[15] IRCCS Santa Lucia Foundation,undefined

[16] University Campus-Biomedico,undefined

[17] Spedali Civili Brescia,undefined

来源：

Alzheimer's Research & Therapy | / 13卷

关键词：

Biomarker; Dopamine; Molecular connectivity; Substantia nigra; Ventral tegmental area;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 246 条

[1] Reisine TD(1978)Pre- and postsynaptic neurochemical alterations in Alzheimer’s disease Brain Res. 159 477-481
[2] Yamamura HI(1997)Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson’s, Alzheimer’s with parkinsonism, and Alzheimer’s disease Mov Disord 12 885-897
[3] Bird ED(1989)The substantia nigra and ventral tegmental area in Alzheimer’s disease and Down’s syndrome J Neurol Neurosurg Psychiatry 52 193-200
[4] Spokes E(1984)Monoaminergic neurotransmitter systems in presenile Alzheimer’s disease and in senile dementia of Alzheimer type Clin Neuropathol. 3 199-205
[5] Enna SJ(1986)Brain dopamine D-1 receptors in senile dementia J Neurol Sci 73 230-62
[6] Joyce JN(2007)Tau and α-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs Acta Neuropathol. 113 53-271
[7] Smutzer G(1983)Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT) Neurobiol Aging. 4 261-393
[8] Whitty CJ(1984)Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia J Neurochem. 43 388-392
[9] Myers A(1983)Monoamine metabolism in senile dementia of Alzheimer type J Neurol Sci. 60 383-312
[10] Bannon MJ(1995)Damage to dopamine systems differs between Parkinson’s disease and Alzheimer’s disease with parkinsonism Ann Neurol Off J Am Neurol Assoc Child Neurol Soc 37 300-32